Trending...
- Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
- Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth
- Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
MCI's total commitment to male contraception now exceeds $3M USD since 2017
DURHAM, N.C. - ncarol.com -- Male Contraceptive Initiative (MCI), a private non-profit foundation, announced four grants, including a grant to Eppin Pharma Inc to support research and development of a male contraceptive, raising MCI's total commitment to male contraception to over $3M USD since 2017.
Eppin Pharma will receive $300,000 to aid in their work developing a novel form of male contraception. Eppin Pharma's product, EP055, is a hormone-free method of contraception that is quickly moving to first-in-human studies. EP055 inhibits sperm motility that is crucial for fertility. The drug is intended to be administered as a pill to men on a daily or on-demand basis, providing protection from pregnancy.
With over $3 million invested in male contraceptive product development, MCI seeks to push male contraceptive research projects towards commercialization. There are a variety of male contraceptive research projects in the drug development pipeline; from early stage screening of drugs to studies that pave the way for early clinical trials, and consistent with their mission, MCI focuses their funding on promising projects within this pipeline like Eppin Pharma's EP055. MCI's mission is to facilitate research and development of male contraceptives for people around the world, and to build awareness among researchers, donors and the general public about the demand for and status of novel male contraceptive methods.
More on ncarol.com
Through its funding efforts, MCI has championed this mission in manifold ways: investing in promising product development through this and other rounds of funding, supporting students and young professionals through fellowships and travel grants, and consistently advocating with the public and media for an increased method mix that includes male contraception.
"More and more men are expressing the desire to participate in contraception with their partners. We are confident that the time is right to emphatically get behind the talent and energy in the field in order to achieve a real vision for a shared contraceptive future," said MCI Executive Director Heather Vahdat.
Dr. Michael O'Rand, CEO and Co-Founder of Eppin added – "We are grateful for the support that MCI has given us and hopeful that this investment in our technology will advance the field of male non-hormonal contraception."
https://www.malecontraceptive.org/
Eppin Pharma will receive $300,000 to aid in their work developing a novel form of male contraception. Eppin Pharma's product, EP055, is a hormone-free method of contraception that is quickly moving to first-in-human studies. EP055 inhibits sperm motility that is crucial for fertility. The drug is intended to be administered as a pill to men on a daily or on-demand basis, providing protection from pregnancy.
With over $3 million invested in male contraceptive product development, MCI seeks to push male contraceptive research projects towards commercialization. There are a variety of male contraceptive research projects in the drug development pipeline; from early stage screening of drugs to studies that pave the way for early clinical trials, and consistent with their mission, MCI focuses their funding on promising projects within this pipeline like Eppin Pharma's EP055. MCI's mission is to facilitate research and development of male contraceptives for people around the world, and to build awareness among researchers, donors and the general public about the demand for and status of novel male contraceptive methods.
More on ncarol.com
- The Sharon at SouthPark Breaks Ground on $178 Million Expansion
- Pattern Recognition In The Arts
- Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
- 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
- Couture Master Perfumer JoAnne Bassett Unveils All-Natural Parfum in Oil Collection in Gift Box
Through its funding efforts, MCI has championed this mission in manifold ways: investing in promising product development through this and other rounds of funding, supporting students and young professionals through fellowships and travel grants, and consistently advocating with the public and media for an increased method mix that includes male contraception.
"More and more men are expressing the desire to participate in contraception with their partners. We are confident that the time is right to emphatically get behind the talent and energy in the field in order to achieve a real vision for a shared contraceptive future," said MCI Executive Director Heather Vahdat.
Dr. Michael O'Rand, CEO and Co-Founder of Eppin added – "We are grateful for the support that MCI has given us and hopeful that this investment in our technology will advance the field of male non-hormonal contraception."
https://www.malecontraceptive.org/
Source: Male Contraceptive Initiative
Filed Under: Health
0 Comments
Latest on ncarol.com
- Couture Master Perfumer JoAnne Bassett Offers Rare Opportunity to Acquire 70 Formula Perfume Codex
- Slotozilla Reports Strong Growth in Q2 2026
- Flexible Plan Investments Names Carl Resnick President
- Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
- Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
- No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
- The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
- Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
- FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
- Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
- New Book Helps Educators Navigate AI in the Classroom While Keeping Humans in Charge
- San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
- LifeTime Asset & Tax Management Named on the 2026 Inc. 5000 List
- Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
- Pastor Miguel Bustillos Brings Deliverance and Exorcism Ministry Conference to Durham, NC
- TOLI CORPORATION's President Visits U.S. to Celebrate Partnerships and Support North American Market
- BumbleBeeSmart Launches Dedicated Sensory Wall Panels Collection for Adults, Memory Care and Senior Living
- BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
- Priority Property Group Becomes Preferred Property Management Partner for Charlotte Investors
- Inlow Upholstery Expands RV and Camper Upholstery Services in Western North Carolina